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Background: Overall survival (OS) and progression free survival (PFS) are key outcome meas-
ures  for head and neck cancer as they reﬂect treatment efﬁcacy, and have implications for
patients and health services. The UK has recently developed a series of national cancer
audits which aim to estimate survival and recurrence by relying on institutions manually
submitting interval data on patient status, a labour-intensive method. However, nationally,
data are routinely collected on hospital admissions, surgery, radiotherapy and chemother-
apy. We  have developed a technique to automate the interpretation of these routine datasets,
allowing us to derive patterns of treatment in head and neck cancer patients from routinely
acquired data.
Methods: We  identiﬁed 122 patients with head and neck cancer and extracted treatment
histories from hospital notes to provide a gold standard dataset. We  obtained routinely
collected local data on inpatient admission and procedures, chemotherapy and radiotherapy
for  these patients and analysed them with a computer algorithm which identiﬁed relevant
time  points and then calculated OS and PFS. We  validated these by comparison with the gold
standard dataset. The algorithm was then optimised to maximise correct identiﬁcation of
each timepoint, and minimise false identiﬁcation of recurrence events.
Results: Of the 122 patients, 82% had locally advanced disease. OS was 88% at 1 year and 77%
at  2 years and PFS was 75% and 66% at 1 and 2 years. 40 patients developed recurrent disease.
Our automated method provided an estimated OS of 87% and 77% and PFS of 87% and 78%
at  1 and 2 years; 98% and 82% of patients showed good agreement between the automatedtechnique and Gold standard dataset of OS and PFS respectively (ratio of Gold standard
to  routine intervals of between 0.8 and 1.2). The automated technique correctly assigned
recurrence in 101 out of 122 (83%) of the patients: 21 of the 40 patients with recurrent disease
were  correctly identiﬁed, 19 were too unwell to receive further treatment and were missed.
Of  the 82 patients who did not develop a recurrence, 77 were correctly identiﬁed and 2 were
incorrectly identiﬁed as having recurrent disease when they did not.
∗ Corresponding author at: Department of Clinical Oncology, Imperial College Healthcare Trust, Charing Cross Hospital, Fulham Palace
Road,  London W6 8RF, UK.
E-mail address: matthew.williams2@imperial.nhs.uk (M. Williams) .
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Conclusions: We have demonstrated that our algorithm can be used to automate the inter-
pretation of routine datasets to extract survival information for this sample of patients. It
currently underestimates recurrence rates due to many patients not being well-enough to
be  treated for recurrent disease. With some further optimisation, this technique could be
extended to a national level, providing a new approach to measuring outcomes on a larger
scale than is currently possible. This could have implications for healthcare provision and
policy for a range of different disease types.
©  2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under
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p.  Introduction
easuring clinical outcomes in cancer patients remains chal-
enging. Studies often report results from single centres, from
arge national studies, or from clinical trials. Single centre
tudies often provide detailed data, but in small numbers of
reated patients, while national studies have more  patients
ut lack details of treatment and outcomes. Clinical trials
ay provide high-quality data, but in small groups of highly
elected patients, and are expensive to perform. Therefore
he challenge remains to report high-quality, detailed clini-
al outcomes in large numbers of patients, without relying on
pecialised data collection.
Head and neck (H&N) cancers represent a large, hetero-
eneous group of cancers with ∼460,000 cases worldwide
1]. Treatment often involves an intensive combination of
urgery, radiotherapy and chemotherapy and patients can suf-
er signiﬁcant long-term side effects. Despite this, tumour
ecurrence rates remain high and survival rates are relatively
oor (National Head & Neck Cancer audit 2011 [2]). Similar treat-
ents may be given at recurrence, depending on the pattern
f recurrence and the patient’s ability to tolerate further treat-
ent, but are toxic and expensive. Therefore, assessment of
reatment efﬁcacy, through measuring recurrence rates and
ecurrence-free survival, is important for patients, clinicians
nd health services.
The UK has had a dedicated national audit database for
&N cancer (DAHNO) since 2004 which requires manual data
ntry. As a consequence, by 2012 only 11.5% of patients had
ata on recurrence (National Head & Neck Cancer audit 2011
2]) Over this time period, the scope and scale of routinely-
ollected electronic healthcare data has expanded, often
riven by the requirement for data for payment systems. In the
K, there are a variety of data sources, including data on hos-
ital admissions and procedures (Hospital Episode Statistics;
ES), radiotherapy (Radiotherapy Dataset; RTDS), chemother-
py (Systemic Anti-Cancer Therapy dataset; SACT) and deaths
Patient Demographics Service; PDS).
Learning how to use these data to answer clinically-driven
uestions, in a timely, accurate and relevant fashion repre-
ents a signiﬁcant challenge [3]. A computerised method of
ccessing and interpreting such data can potentially yield use-
ul clinical patterns and outcomes that are currently measured
y national audits at considerable expense.
We have previously described a pilot study presenting a
ethod of estimating recurrence and survival in H&N cancer
atients based on manual analysis of routine data in a smallthe CC BY license (http://creativecommons.org/licenses/by/3.0/).
group of 20 patients [4]. This work was based on capturing clin-
ical intuitions about patterns of care and treatment in the form
of simple rules about intervals between different treatment
types. Since the routinely available data do not contain infor-
mation on treatment intent, potentially curative treatments
that were close to each other in time were assumed to be as
part of a planned pattern of sequential, curative treatments,
whereas if there was a signiﬁcant gap between initial curative
treatment and subsequent treatment, that subsequent treat-
ment was assumed to be for recurrent disease. However, the
assumptions underlying this approach are unlikely to be uni-
formly correct, and have never been validated in a large patient
group.
In this study we:
1. Extend the range of clinical intuitions that we  capture in
computational form
2. Introduce a novel computer-based automated framework,
written in Python, to merge  and interpret the routine
data and automatically identify diagnosis and recurrence
events/dates;
3. Use that as a basis for performing simple in silico exper-
iments to validate and optimise our approach in a larger
patient sample (n = 122).
2.  Method
2.1.  Patient  group
Patients from a single cancer centre (UCLH, London), were
included if their ﬁrst diagnosis of H&N cancer was made
between 2009–2012, they had radiotherapy given with radi-
cal intent (either as primary modality or for recurrence), we
were able to identify their date of diagnosis, they attended
at least one follow-up visit at UCLH post-diagnosis, and they
had an eligible histological subtype (squamous cell carcinoma,
undifferentiated nasopharyngeal carcinoma, adenoid cystic
carcinoma). The identiﬁcation and exclusion of patients is
shown in Fig. 1.
2.2.  Creation  and  manual  analysis  of  gold  standard
datasetWe  manually extracted data on patient characteristics, stag-
ing and treatment from hospital records. The date of diagnosis
was the date that the ﬁrst diagnostic specimen was obtained.
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Fig. 1 – Patient identiﬁcation and selection ﬂowchart.
chronologically, and used as the basis for estimating OS and
PFS. For the purposes of this study, we  compared the outputThe date of recurrence was the earliest date that recur-
rence was conﬁrmed, on clinical, radiological or histological
grounds. The date of last follow-up was the latest date of
known contact with the hospital. The overall survival interval
was the time between diagnosis and death or last follow-up.
The progression-free survival interval was the time between
diagnosis and evidence of recurrent or progressive disease
(see Fig. 2, upper half). Patients who were lost to follow-up, or
were alive at the conclusion of the study were censored at the
time of last known follow-up (according to the Kaplan–Meier
method). This provided a “Gold standard” dataset of manually
curated and analysed data. b i o m e d i c i n e 1 1 7 ( 2 0 1 4 ) 412–424
2.3.  Routine  dataset
We obtained local data sources for each patient from the Hos-
pital Information Department, UCLH. These were:
1. Personal demographic service (PDS): notiﬁcation of death,
and date of death if dead
2. Hospital episode statistics (HES): records of start and end
dates of admissions and inpatient procedures and diag-
noses
3. Chemotherapy data (SACT): records of administration of
chemotherapy and diagnoses and dates of treatments
4. Radiotherapy data (RTDS): records of delivery of radiothe-
rapy and diagnoses and dates of treatments.
All data sources use the International Classiﬁcation of Dis-
eases v 10 (ICD-10) for diagnostic information. HES uses the
Ofﬁce of Population and Census Classiﬁcation of Interventions
and Procedures v 4 (OPCS-4). ICD-10 is widely used interna-
tionally, and both have mappings to other terminologies such
as SNOMED-CT.
Our algorithm integrated the extracted HES, SACT, RTDS
and PDS data to form a single list of event data for each
patient, comprising diagnostic (ICD-10) and interventional
codes (OPCS 4.4). The events were arranged in chronologi-
cal order and ﬁltered to ensure only treatments relevant to
head and neck cancer were analysed (according to ICD10 codes
relating to malignant neoplasms of the head, face or neck
as displayed in Appendix 1.1). This information was used to
inform the development of our algorithm.
2.4.  Automated  interpretation  of  routine  data
None of the routine data sources (RTDS, SACT, HES and PDS)
directly report either date of diagnosis or date of disease
recurrence, and so we  deﬁned proxy time points for relevant
clinical events. Automated strategies were used to identify
these proxy time points and thus estimate survival.
Date of diagnosis was taken to be the date of the ﬁrst
recorded ICD-10 code in HES that corresponded to a diagnosis
of head and neck malignancy (see Appendix 1.1).
Date of recurrence.  We used the start date of secondary
treatment for HNSCC (whether surgery, radiotherapy or
chemotherapy) as a proxy for recurrence. We initially deﬁned
a treatment as being for a recurrence if it was given more  than
90 days after the end of the previous treatment if two  treat-
ments occurred within this time interval they were considered
to form a planned primary treatment strategy, otherwise the
later treatment was assumed to be treatment for recurrent
disease.
All routine data (HES, SACT, RTDS and PDS) were extracted
on a per-patient basis. Blank entries were removed. Radiothe-
rapy and chemotherapy data were summarised and orderedof software with the manually curated gold standard dataset
to allow us to assess the accuracy of the automated approach.
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Fig. 2 – Deﬁnition of progression free survival and overall survival for the Gold standard and routine datasets.
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a.5.  Optimisation  of  automated  method
e  further optimised our approach through use of a time-
ased threshold to distinguish between a series of primary
reatments, which may follow on from one another, and treat-
ents given in response to disease recurrence. Our manual
ilot study [4] used a static time interval of 90 days between
onsecutive treatments to distinguish delayed primary treat-
ent from treatment for recurrence. In this work, we  explored
ystematic optimisation of this time interval via in silico
xperimentation. Since both diagnosis and recurrence are
ften preceded by coded diagnostic procedures, we investi-
ated whether backdating diagnosis and recurrence would
mprove estimated OS and PFS. We backdated the date of diag-
osis or recurrence to the earliest of:
. The date of the earliest diagnostic procedure within a set
time interval of a treatment for H&N cancer; this time inter-
val was initially set at 42 days, and then varied to ﬁnd the
optimal interval.
. The ﬁrst date of metastatic disease (determined by the
appearance of a metastatic cancer ICD-10 code in HES,
appendix 1.1).
. The start of radiotherapy for an H&N cancer.
Since a longer backdating time interval risks inclusion of
rrelevant diagnostic procedures, we  attempted to ﬁnd the
hortest time interval (used for backdating for both diagnosis
nd recurrence) consistent with the optimal agreement with
he gold standard data. For each experiment, overall survival
nd progression-free survival intervals were calculated usingthe proxy diagnosis and recurrence time points as illustrated
in Fig. 2 (lower half). We assessed the impact of our experi-
ments based on the agreement between the automated results
and the gold standard data in three areas:
1. Recurrence events (assessed by calculating the proportion
of patients in whom the recurrence was correctly detected
by the automated data vs. the gold standard).
2. Overall survival interval (calculated on an individual
patient basis); we  found the survival intervals in the gold
standard and the routine data set, and took the ratio. In
line with other work [5,6] a ratio of 0.8–1.2 was taken to
represent reasonable agreement.
3. Progression-free survival interval (calculated individually
and presented as a ratio, as for overall survival time).
Since we  could not assume that correlation was normally
distributed we used Kendall’s tau to assess correlation using
the statistical software, R [7].
The routine data was supplied as a set of text (CSV) ﬁles. We
wrote our own software (in Python v3.2) to integrate data from
the different data sources, to automatically identify diagno-
sis and recurrence time points, to calculate survival intervals,
and to determine the agreement between the automatic anal-
ysis and the gold standard dataset. These results were then
exported as a text ﬁle for subsequent analysis in the open-
source statistics software, R. Fig. 3 shows the ﬂow of data
through the automated software.
The software requires ﬁve sets of input data:
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Fig. 3 – Flow chart of python software for the automated identiﬁcation of diagnostic and recurrence time points from routine
data. The section in the lower half of the ﬁgure, referring to the integration of routine and gold-standard data, was to allow
.us to assess the accuracy of the routine-data based approach
• A list of anonymised patient identiﬁers, used to allow us to
link data from different sources
• Routine data sources (from HES, SACT, RTDS and
PDS)• Look-up tables to translate ICD10 and OPCS codes to text
(Appendices 1.1 and 1.2)
• A list of procedures that are not considered signs of recur-
rence (Appendix 1.3)
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Table 1 – Staging data for patients included in the study.
Tumour site Total Stage I Stage II Stage III IVa IVb IVc Unknown
Oropharynx 51 0 1 5 37 2 1 5
Larynx 26 10 2 4 9 0 0 1
Hypopharynx 13 0 0 1 9 1 1 1
Oral cavity 13 1 0 0 10 0 0 2
1 3 6 1 0 8
4 13 71 4 2 17
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Fig. 4 – Effect of modifying time interval for backdating
diagnosis date to biopsy procedure on the number of
patients with estimated date within one month of Gold
standard date. No improvement was seen for diagnosis
dates in perfect agreement or within 1 week’s agreement
adjuvant treatment and treatment of recurrent disease also
gave the best agreement between the gold standard and
automated PFS intervals (Fig. 6). Since this did not increaseOther sites or primary unknown 19 0 
Total 122 11 
 A list of diagnostic procedures (e.g. biopsy: Appendix 1.4).
.  Results
22 patients met  the inclusion criteria (Fig. 1). The median age
as 61 (range 20–82) and 82% of the patients presented with
ocally advanced disease (stages III–IV). The tumour sites and
taging data are presented in Table 1. 40 of the patients devel-
ped recurrent or progressive disease. Overall survival was
8% at 1 year and 77% at 2 years. Progression-free survival was
5% and 66% at 1 and 2 years. Our initial, automated, unopti-
ised method provided: an estimated OS of 87% and 77% and
FS of 87% and 78%: 21 of the 40 patients with recurrent dis-
ase were correctly identiﬁed and 19 were missed; of the 82
atients who did not develop a recurrence, 77 were correctly
dentiﬁed and 5 were incorrectly identiﬁed.
.1.  Optimisation  of  automated  method
.1.1.  Optimisation  by  backdating  strategy
e  investigated the impact of backdating the date of diagnosis
nd recurrence to the date of biopsy, radiotherapy treatment
r date of presentation with metastatic disease. The results
f this are summarised in Table 2. Backdating to the date
f biopsy improved the number of patients in whom the
ates of diagnosis and recurrence were in agreement with
old-standard data, as did backdating to the start of radio-
herapy. Backdating to a diagnosis of metastatic disease had
o impact, and we  therefore disregarded it in further analy-
is. Combining backdating to biopsy or start of radiotherapy
esulted in a modest improvement in performance above our
nitial technique, reducing the number of patients where there
as signiﬁcant error (ratio of automated/gold standard out-
ide 0.8–1.2) in OS and PFS interval by 57% and 8% respectively.
owever, none of the backdating strategies improved the iden-
iﬁcation of disease recurrence.
.1.2.  Optimisation  of  time  intervals  for  backdating  biopsy
ince backdating to biopsy and start of radiotherapy by up to
 weeks improved performance modestly, we systematically
aried the interval from 14 to 70 days, in 14 day increments.
n the basis of this, a time interval of 56 days was the shortest
nterval with the best agreement with the gold standard data
or both diagnosis and recurrence (Figs. 4 and 5). Altering the
ime intervals used for backdating improved the agreement of
ates further, but did not improve the number of patients in
hom we  detected recurrence.upon modifying the biopsy backdating time interval.
3.1.3.  Use  of  time  interval  after  end  of  primary  treatment
to deﬁne  secondary  treatment
The results of optimal deﬁnition of the interval between
one treatment and another to distinguish between planned
adjuvant treatment and treatment for recurrent disease are
displayed in Table 3. We  aimed to minimise the incorrect
classiﬁcation of adjuvant treatment and to maximise cor-
rect identiﬁcation of treatment for recurrent disease. A time
interval of 120 days resulted in the fewest recurrence event
disagreements (21) and falsely identiﬁed recurrence events
(n = 2 events). This results in an optimal speciﬁcity of 97.6%
and sensitivity of 52.5% for detecting recurrence events.
Using a 120-day interval to differentiate between plannedFig. 5 – Effect of modifying time interval for backdating
recurrence date to biopsy procedure.
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Fig. 6 – Effect of modifying time interval for deﬁning
secondary treatment on the number of patients for whom
there was disagreement as to recurrent disease status
between the Gold standard and routine datasets, and the
number of patients with PFS intervals which were
signiﬁcantly different to those in the Gold standard dataset.the number of recurrences missed and minimised the num-
ber incorrectly ascribed (see Table 3), this appears to be the
optimal time-period in this group of patients.
3.1.4.  Summary
The best agreement between the automated analysis and
manual analysis of the gold standard data came from:
1. Backdating to a diagnostic event to no more  than 56 days
prior to the ﬁrst evidence of a H&N cancer diagnosis code.
2. Backdating to radiotherapy with no time limit.
3. Assuming that treatment was for recurrent, rather than ini-
tial, disease if it occurred more  than 120 days following the
primary diagnosis.
Table 4 displays the results of the ﬁnal optimised auto-
mated strategy.
We further stratiﬁed the results to see the inﬂuence on
tumour type on successful identiﬁcation of recurrence; results
displayed in Table 5. We  successfully predicted 78% of recurr-
ences in laryngeal cancer, 54% in oropharynx- and 67% in oral
cavity cancers. This is probably as laryngeal cancer tends to
present at an earlier stage (and in our sample was the sub-
site with the largest number of patients with stages I and II
disease) and therefore recurrences would be amenable to fur-
ther radical treatment. This suggests that even though most of
the patients in our sample had advanced disease, our method
would be relatively robust if more  early stage cancers were
included.
3.2.  Survival  and  recurrence  data
There was good correlation for OS and PFS between the two
datasets as displayed in Fig. 7. For OS, Kendall’s tau was 0.97
(p-value < 0.0001), and for PFS, tau = 0.82 (p-value < 0.0001).
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Table 3 – Number of recurrence date and event disagreements (the recurrence status of the patient is different in the gold
standard and automated data), correctly identiﬁed (automated and gold standard both identify recurrence), falsely
identiﬁed (automated data contains a recurrence not present in the gold standard data) and missed (automated data does
not contain a recurrence that is present in the gold standard).
Time interval
(days)
Recurrence dates in
agreement {n = 40} ± 1
week/ ± 1 month
No. of recurrence
events correctly
identiﬁed
No. of recurrence
events falsely
identiﬁed
No. of recurrence
events missed
Sensitivity Speciﬁcity
60 1 week (6)
1 month (8)
21  11 19 52.5% 86.6%
90 1 week (7)
1 month (9)
21  5 19 52.5% 93.9%
120 1 week (7)
1 month (9)
21  2 19 52.5% 97.6%
150 1 week (6)
1 month (8)
19  2 21 47.5% 97.6%
180 1 week (4)
1 month (5)
13  2 27 32.5% 97.6%
Fig. 7 – (i) Overall survival and (ii) progression free survival intervals of the automated routine data plotted against Gold
s
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.3.  Comparison  of  optimised  automated  technique
nd gold  standard
8% and 82% of patients showed good agreement between the
utomated technique and Gold standard dataset of OS and
FS respectively (ratio of Gold standard to routine intervals
f between 0.8 and 1.2). 61 diagnosis dates out of 122 were
orrect to the nearest week of the true date. The automated
echnique correctly assigned recurrence in 101 out of 122 (83%)
f the patients. Of the 40 patients who developed a recurrence,
1 were identiﬁed by the automated technique. Of these, four
ates were perfectly identiﬁed, seven were within 1 week and
ine were within 1 month of the Gold standard dataset. The
utomated technique failed to detect 19 patients who devel-
ped a recurrence, and incorrectly inferred that two patients
ad developed a recurrence when they had not.
.  Discussion
e  have automated and optimised a novel computer-based
pproach for estimating disease-recurrence in head and neck
ancer through a series of experiments. An earlier pilot study
uggested that our approach may have some validity. This
tudy has conﬁrmed its feasibility in a larger group of patientsusing an automated approach, and has documented the
speciﬁc impact of a range of automatic backdating strategies
on the performance of our approach. The ﬁnal automated
approach successfully identiﬁed recurrence status in 83% of
patients, and 98% and 82% of patients showed good agree-
ment between the automated technique and gold standard
dataset of OS and PFS respectively (ratio of gold standard to
routine intervals of between 0.8 and 1.2).
Our optimisation procedure showed small yet measurable
improvements in estimating OS and PFS intervals over the
unoptimised technique. The diagnosis date was generally later
than that for the gold standard by a median of 2 days, and the
estimated OS interval was more  than 20% different from the
gold standard OS interval for only three patients. Backdating to
biopsy was found to improve diagnosis date agreement; with-
out backdating to biopsy the routine diagnosis date preceded
that for the Gold standard by a median of 5 days.
However, backdating did not improve the proportion of
patients who developed recurrent disease but were not
detected by our approach. Of the 19 patients with recurrent
disease who were missed, 16 (79%) of these failed cases were
due to the patient not receiving treatment for their recurrence.
One other was because the patient suffered from early recur-
rence 41 days after primary treatment and so a secondary
treatment was assumed, following our automated technique,
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to be planned primary treatment. Another missed recurrence
had an incorrect ICD10 code, and the ﬁnal missed recurrence
was because the surgical treatment of recurrence was mis-
coded as a reconstructive procedure. Two recurrences were
falsely detected in the routine data due to: (i) a wrong diagno-
sis codes (HN cancer rather than lung cancer) being assigned a
radiotherapy treatment, and (ii) a patient receiving treatment
coded as chemotherapy one year after primary radiotherapy,
which was therefore used as an indication of recurrence by our
automated approach. These results are summarised in Table 5.
There are several limitations to this work. Firstly, we  have
only looked at patients from one cancer centre in the UK,
and we have concentrated our work on patients at higher risk
of recurrence, rather than using a random sample. It will be
important to assess the performance of our system in an unse-
lected population, particularly in those with a lower risk of
recurrence. However, we chose to use data which are available
at a national level in the UK, and are based on widely used
standards (OPCS, ICD-10), so that that they could be reason-
ably easily replicated. In particular, we  have not used clinically
important data which are not currently reliably collected in
routine care, such as cancer stage. In addition, we  accept that
our results may not generalise to other populations. Our tech-
nique has moderate performance. It is not clear what level
or performance is necessary for the technique to be clinically
applicable, and previous studies have not examined perfor-
mance in detail. We  suspect that even having broad estimates
may be useful, but there are also clear areas for development
which are the focus of on-going work.
Aside from the speciﬁc problems in this dataset, there are
two main problems in using routine health-care data for clin-
ical purposes. The ﬁrst is that such data, often collected by
staff who are not involved in direct clinical care, may not accu-
rately reﬂect the clinical situation. In our dataset, these were
the causes for three of the errors. In theory, these could be
reduced by training and increasing clinical involvement (see
[8] for a discussion). The second source of error is in the mis-
match which occurs in using administrative data for clinical
purposes. These data are collected to inform payment and
billing operations, rather than clinical care, and using them for
clinical purposes often requires some degree of inference. In
systematic terms, the development of progressive/recurrent
disease is not directly captured in the routine data, and thus
we infer recurrence from diagnostic and treatment activity
that happens as a result. In this dataset, there was a speciﬁc
instance where a patient received a high-cost drug regimen
in the intensive care unit, which was coded as “chemother-
apy”. The degree to which these inferences can be generalised
and extended remains unclear, and is to some extent probably
disease and health-care system speciﬁc.
Previous work in this area is extremely limited. Other
authors have shown that routinely collected data can be
used to estimate mortality rates, related to either different
oncological treatments [9] or following orthopaedic surgical
procedures [10]. There has also been work showing that can-
cer registry data can be used to measure recurrence rates in
breast cancer [11]. However, there is very little work on using
routinely available procedure-level data to infer disease recur-
rence. One study examined the use of such data to estimate
measures of metastatic disease in breast, prostate and lung
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Table 5a – Recurrence events correctly predicted and missed for each tumour site.
Tumour site Total Recurrences not
predicted
Recurrence correctly
predicted
% recurrence
correctly predicted
Oropharynx 51 6 7 54
Larynx 26 2 7 78
Hypopharynx 13 6 1 14
Oral cavity 13 1 2 67
Other sites or primary unknown 19 4 4 50
Total 122 19 21 53
Table 5b – Numbers and causes of the failure of our automated approach.
Failure Number of
patients {n = 122}
Reason for failure
Recurrence falsely identiﬁed 2 •Incorrect diagnosis ICD10 code assigned (HN cancer instead of
lung cancer) {n = 1}
•Primary chemotherapy treatment received 1 year after
primary radiotherapy–wrongly detected as treatment for
recurrence {n = 1}
Recurrence event missed 19 •No treatment for recurrence {n = 16}
•Incorrect diagnosis ICD10 code assigned (disorders of nose
J348) {n = 1}
•Early recurrence (41 days after primary treatment) {n = 1}
•Treatment surgery miscoded as reconstructive procedure
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tancer [12], and used a combination of ICD-9 codes for diseases
nd treatment codes for chemotherapy. The other study used
atients enrolled in a clinical trial, and looked at their routine
ealth claims data to estimate recurrence and death [13]. They
ound a good rate of agreement, with the routine healthcare
ata being able to measure the 5-year disease-free survival
ate with a substantial degree of accuracy. In both cases, the
uthors used a combination of clinical intuition and logically-
escribed criteria to use the routine data to infer recurrence.
his approach is similar in principle to our work, although we
ncluded a wider range of treatment modalities than either of
heir studies did, and is the only one to include patients with
ead and neck cancers.
Our work has focused on head and neck cancer, where local
ecurrence is relatively common and rarely left untreated.
owever, we  believe that our approach is applicable to other
umour sites, and possibly non-malignant diseases. Although
here are some disease-speciﬁc aspects to the work (for
xample, the presentation of disease with initial lymph-node
nvolvement in the neck), the principle of retrospectively
ssigning a date of diagnosis to a primary tumour based on
he (earlier) date of presentation of metastatic disease would
eem to be applicable across multiple tumour sites. Simi-
arly, the use of repeated treatments to measure recurrent
isease is one that is potentially applicable to a wide vari-
ty of conditions where recurrence is a possibility. However,
t is restricted to those patients who are able or willing to
eceive subsequent treatments, and there are a proportion of
atients who  are either unwilling or unable to undergo further
reatment, and thus will not be detected by our approach. Cur-
ently, our approach offers reasonable performance in a group
f patients who are well enough to undergo initial curative
reatment. There remain further possibilities for optimisa-
ion, through a more  individualised assessment of relapse,{n = 1}
and cross-referencing data on overall survival and local recur-
rence. These, and other developments, remain the subject of
further work.
5.  Conclusions
We  have developed a computer-based automated technique
to extract data on relevant clinical events from routine
healthcare datasets (HES, SACT, RTDS and PDS). Diagnosis,
recurrence and death dates, and date of last follow-up were
identiﬁed and overall survival and progression free survival
intervals were calculated from this data. The automated algo-
rithm was optimised to maximise correct identiﬁcation of
each timepoint, and minimise false identiﬁcation of recur-
rence events. We  tested our algorithm on 122 patients who had
received radical treatment for head and neck cancer; the recur-
rence status for 82% patients was correctly identiﬁed, and in
98% of patients there was acceptable agreement between the
routine and gold standard dataset for overall survival inter-
vals (83% for progression free survival). 21 recurrence events
were correctly identiﬁed out of a total of 40. The 19 who  were
missed were mainly due to the patient not receiving treatment
for their recurrence; secondary treatment was used as an indi-
cator for recurrence in the algorithm. We have demonstrated
that our algorithm can be used to automate interpretation of
routine datasets to extract survival information for this sam-
ple of patients, and the coding schemes and approach that the
technique uses opens it up to use at a national level. There is
potential to develop this algorithm to sensitise the recurrence
dating strategy to contraindications of the patient, and also
to perform retrospective analysis by predicting likelihood of
recurrence through knowing the ﬁnal status of the patient.
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Metastasis ICD10 Codes
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d neck malignancy and evidence of metastasis.
Description
s of lip, oral cavity and pharynx
s of nasal cavity, middle ear, sinuses and larynx
s of ill-deﬁned, secondary and unspeciﬁed sites–head, face and neck
ciﬁed malignant neoplasm of lymph nodes of head, face and neck
ciﬁed malignant neoplasm of lymph nodes
 neoplasm of respiratory and digestive organs
 neoplasm of other sites
ence if given as second modality treatment.
Description
n of septum of nose
tomy, partial pharyngectomy
my, partial laryngectomy, laryngectomy NEC
ial laryngectomy
ction/destruction of lesion of larynx
tion of lesion of lip
y, partial glossectomy, hemiglossectomy, glossectomy NEC
tion of lesion of tongue
ion tonsillectomy, guillotine tonsillectomy, laser
on/unspeciﬁed/destruction of tonsil
herapy of lesion of upper GI tract, extirpation/snare resection/laser
terisation/sclerotherapy/destruction of lesion of upper GI tract
 of cervical lymph nodes
edial maxillectomy, other speciﬁed excision of maxilla, excision of
ctomy, extensive excision of mandible, mandibulectomy, partial
dible
therapy
adiotherapy
drugs for chemotherapy
otherapy
herapy of lesion of organ
current H&N disease.
Description
Neurophysiological operations
358,
Vein and artery-related operations
Maintenance/operations of catheter
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Table A.1.3 (Continued)
Procedure type OPCS 4.4 codes Description
U181-U183, U188, U189 Imaging of breast
U191-U199, U201-U206, U208, U209 Electrocardiography operations
U301, U302, U308, U309
U311, U318, U319 Cardiovascular testing
U321, U328, U329, X360-X363, X368, X369 Pacemaker testing
Blood tests, blood withdrawal
Adjunctive procedures F091-F095, F098, F099, F101-F104, F108,
F109
Tooth extraction, dental clearance
G342 Creation of temporary gastrostomy
Blood transfusion, blood stem cell transplant
X331-X336, X338, X339
Reconstructive procedures F081-F084, F088, F089 Implantation of tooth
F631-F635, F638, F639 Fitting/insertion/adjustment of denture or
obturator
Table A.1.4 – OPCS codes that represent a histological diagnosis procedure.
OPCS 4.4 codes Description
C061, C106, C117, C222, C244, C263 Biopsy of eye region
D123, D201, D281 Biopsy of ear region
E033, E045, E095, E101, E134, E173, E202 Biopsy of nasal region/adenoids
E251, E252, E271, E334, E361, E368, E369, E371, E491 Biopsy of pharynx, nasopharynx and larynx, lower
respiratory tract
F062, F203, F241, F321, F362, F421, F481 Biopsy of lip, gingiva, tongue, palate, tonsil, mouth,
salivary gland
G131, G161, G191, G451 Biopsy of oesophagus, upper GI
J091, J092, J131, J132, J141, J171, J723 Biopsy of liver, spleen
S131, S132, S138, S139, S141-S144, S148, S149, S151, S152 Biopsy of skin/skin of head and neck region
T092, T141 Biopsy of pleura
T872 Biopsy of cervical lymph node
V194, V133 Biopsy of mandible, bone of face
E253, E258, E259 Endoscopic examination of nasopharynx
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